- Home
- CRGX
as 11-15-2024 4:00pm EST
Stocks
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 964.5M | IPO Year: | 2023 |
| Target Price: | $30.33 | AVG Volume (30 days): | 167.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.56 - $33.92 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of CARGO Therapeutics Inc. (CRGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Radhakrishnan Anup | CRGX | Chief Financial Officer | Sep 18 '24 | Sell | $25.28 | 1,600 | $40,452.00 | 6,446 | |
| Chapman Gina | CRGX | President & CEO | Sep 18 '24 | Sell | $25.06 | 10,141 | $254,231.69 | 103,905 |
Latest CARGO Therapeutics Inc. News
CRGX Breaking Stock News: Dive into CRGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
11 days ago
CARGO Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
12 days ago
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
Simply Wall St.
a month ago
Here's Why We're Not Too Worried About CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn Situation
Motley Fool
3 months ago
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
GlobeNewswire
3 months ago
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Simply Wall St.
4 months ago
With 54% ownership of the shares, CARGO Therapeutics, Inc. (NASDAQ:CRGX) is heavily dominated by institutional owners
MT Newswires
4 months ago
HC Wainwright Initiates CARGO Therapeutics With Buy Rating, $33 Price Target
Compare CRGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRGX CARGO Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.